Effect of General Anesthesia on Enterocyte Damage

NCT ID: NCT02199275

Last Updated: 2014-07-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-08-31

Study Completion Date

2014-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

During non urgent surgery, general anesthesia might induce enterocyte damage. I-FABP is a performant biomarker of enterocyte damage. We aimed to study whether patient ongoing general anesthesia for non-urgent surgery have an elevation of plasma I-FABP concentration.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Inclusion criteria

* Indication of non-urgent surgery
* General anesthesia protocol using propofol and remifentanyl
* One half of the patients have a history of ischemic arteriopathy
* One half of the patients have no history of ischemic arteriopathy

Exclusion criteria

* Age \< 18 years old
* Pregnant

Primary objective

Is there a significant elevation of I-FABP between the pre-anesthesic period and 11 minutes after induction of general anesthesia ?

Secondary objectives

1. Is I-FABP elevation higher among patients with history of patent arteriopathy ?
2. Is I-FABP elevation higher among patients presenting with hypotension during anesthesia ?

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-urgent Surgery General Anesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Indication of non-urgent surgery
* General anesthesia protocol using propofol and remifentanyl
* One half of the patients have a history of ischemic arteriopathy
* One half of the patients have no history of ischemic arteriopathy

Exclusion Criteria

* Age \< 18 years old
* Pregnant
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire de Besancon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gael PITON

MCU-PH

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHRU de Besançon

Besançon, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Gaël Piton, MD

Role: primary

0033381668127

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P/2013/174

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Depth of Anesthesia and Proteomics
NCT05380778 COMPLETED NA
Propofol and Perioperative Inflammation
NCT01115179 COMPLETED PHASE4